The Heat Shock Protein 70 pipeline drugs market research report outlays comprehensive information on the Heat Shock Protein 70 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Heat Shock Protein 70 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Infectious Disease, Cardiovascular, and Central Nervous System which include the indications Melanoma, Breast Cancer, Coronavirus Disease 2019 (COVID-19), Viral Infections, Myocardial Infarction, Acute Ischemic Stroke, Traumatic Brain Injury, and Tauopathies. It also reviews key players involved in Heat Shock Protein 70 targeted therapeutics development with respective active and dormant or discontinued products.
The Heat Shock Protein 70 pipeline targets constitutes close to 26 molecules. Out of which, approximately 19 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Preclinical, and Discovery stages are 1, 3, 11, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 2 molecule.
Heat Shock Protein 70 overview
HSP70 are a family of conserved ubiquitously expressed heat shock proteins. This class of molecular chaperons is found in both prokaryotes and in several compartments of eukaryotic cells. These proteins can interact with polypeptides during a variety of assembly processes in such a way as to prevent the formation of nonfunctional structures.
For a complete picture of Heat Shock Protein 70’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
